<div id="readability-page-1"><p>Omeros Corporation (NASDAQ:OMER - Get Free Report) has earned a consensus recommendation of &#34;Moderate Buy&#34; from the five ratings firms that are currently  covering the company, MarketBeat Ratings reports. One investment analyst  has rated the stock with a sell recommendation, one  has given a hold recommendation, two have assigned  a buy recommendation and one  has given a strong buy recommendation to  the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $33.6667.</p><ul><li>Breakout Momentum Plays You Need to Know About</li></ul><p>A number of analysts recently commented on the company. Needham &amp; Company LLC  reaffirmed a &#34;hold&#34; rating on shares of Omeros in a research report on Wednesday, October 15th. HC Wainwright  restated a &#34;buy&#34; rating on shares of Omeros in a research note on Wednesday, December 24th. D. Boral Capital  reiterated a &#34;buy&#34; rating and set a $36.00 target price on shares of Omeros in a research note on Wednesday, December 24th. Wall Street Zen raised shares of Omeros from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, December 13th. Finally, Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Omeros in a research report on Wednesday, October 8th.</p><p><b>Read Our Latest Stock Analysis on Omeros</b></p><h2>Omeros Price Performance</h2><p>Shares of OMER stock opened at $17.17 on Friday. The firm has a 50-day moving average of $9.79 and a 200-day moving average of $6.18. Omeros has a one year low of $2.95 and a one year high of $17.65. The company has a market cap of $1.22 billion, a P/E ratio of -8.50 and a beta of 2.37. </p><p>Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.39.  As a group, research analysts expect that  Omeros will post -3.09 earnings per share for the current fiscal year. </p><h2>Institutional Investors Weigh In On Omeros</h2><p>Several large investors have recently modified their holdings of OMER. Russell Investments Group Ltd. raised its holdings in shares of  Omeros by 113.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 5,677 shares during the period.  Trexquant Investment LP purchased a new stake in  Omeros in the first quarter worth $88,000.  B. Riley Wealth Advisors Inc. purchased a new stake in  Omeros in the second quarter worth $32,000.  Tower Research Capital LLC TRC raised its stake in shares of  Omeros by 829.6% in the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company's stock valued at $40,000 after buying an additional 11,971 shares during the period.  Finally, Sei Investments Co. purchased a new position in shares of  Omeros during the 2nd quarter valued at $40,000. Hedge funds and other institutional investors own  48.79% of the company's stock. </p><h2>Omeros Company Profile</h2> (Get Free Report)<p>Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.  </p><p>Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Omeros</li><li>Trump’s new AI budget just passed — one stock could soar</li><li>Bombshell Exposé on China Strikes</li><li>Do not delete, read immediately</li><li>Buy this $2 Gold Stock Before January 1, 2026</li><li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01FUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01FUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Omeros Right Now?</h2><p>Before you consider Omeros, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.</p><p>While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

OMER

<p>Omeros Corporation (NASDAQ:OMER) has received a consensus rating of "Moderate Buy" from five brokerages. One analyst rated it as a sell, one as hold, two as buy, and one as strong buy. The average 12-month price target is $33.67. Recent ratings include a hold from Needham & Company and a buy from HC Wainwright. Omeros reported a quarterly EPS of ($0.19), exceeding estimates. The company focuses on developing therapeutics for inflammation and CNS disorders, with its first product, Omidria®, approved by the FDA.</p>

Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages